Faron Pharmaceuticals Oy
FPHAF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $20 | $21 | $17 |
| G&A Expenses | $0 | $9 | $7 | $10 |
| SG&A Expenses | $0 | $9 | $7 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$1 | -$6 |
| Operating Expenses | $0 | $29 | $27 | $21 |
| Operating Income | -$0 | -$29 | -$27 | -$21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$2 | -$1 | -$0 |
| Pre-Tax Income | -$0 | -$31 | -$29 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$31 | -$30 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.341 | -0.381 | -0.291 |
| % Growth | 99.9% | 10.4% | -31% | – |
| EPS Diluted | -0 | -0.341 | -0.381 | -0.291 |
| Weighted Avg Shares Out | 89 | 79 | 67 | 61 |
| Weighted Avg Shares Out Dil | 89 | 79 | 67 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$28 | -$27 | -$21 |
| % Margin | – | – | – | – |